01
What the evidence says
Large systematic reviews generally find little or no meaningful reduction in overall cardiovascular events or mortality from increasing long-chain omega-3 with common supplements for broad primary or secondary prevention, although estimates differ by outcome and study. Some prescription formulations at specific doses and in selected high-risk groups have separate trial results and should not be generalized to retail fish oil.
Sources for this section: [1]
02
How to use the finding
For most people seeking prevention, discuss the overall dietary pattern and proven risk-factor treatment before adding a capsule. If a clinician recommends a prescription omega-3 product for high triglycerides or another indication, confirm the exact formulation, dose, expected outcome, and monitoring. A supplement label saying fish oil or omega-3 does not identify an equivalent intervention.
Sources for this section: [1]
03
Limits and open questions
Products vary in EPA, DHA, oxidation, contaminants, and actual dose. Gastrointestinal effects are common; higher doses may affect bleeding and some trials report more atrial fibrillation. Fish allergy, anticoagulants, surgery, pregnancy, sustainability, and product testing matter. Association between fish intake and health cannot establish that isolated supplement capsules reproduce the same benefit.
Sources for this section: [1]
Sources
- Omega-3 fatty acids for the primary and secondary prevention of cardiovascular diseaseCochrane Database of Systematic Reviews · 2020DOI 10.1002/14651858.CD003177.pub5